These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17936335)

  • 1. Risks to aquatic organisms posed by human pharmaceutical use.
    Kostich MS; Lazorchak JM
    Sci Total Environ; 2008 Jan; 389(2-3):329-39. PubMed ID: 17936335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting variability of aquatic concentrations of human pharmaceuticals.
    Kostich MS; Batt AL; Glassmeyer ST; Lazorchak JM
    Sci Total Environ; 2010 Sep; 408(20):4504-10. PubMed ID: 20619877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment.
    Cunningham VL; Binks SP; Olson MJ
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):39-45. PubMed ID: 19013494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human pharmaceuticals in US surface waters: a human health risk assessment.
    Schwab BW; Hayes EP; Fiori JM; Mastrocco FJ; Roden NM; Cragin D; Meyerhoff RD; D'Aco VJ; Anderson PD
    Regul Toxicol Pharmacol; 2005 Aug; 42(3):296-312. PubMed ID: 15979221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing emissions of active pharmaceutical ingredients from manufacturing facilities: an environmental quality standard approach.
    Murray-Smith RJ; Coombe VT; Grönlund MH; Waern F; Baird JA
    Integr Environ Assess Manag; 2012 Apr; 8(2):320-30. PubMed ID: 22057894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritising pharmaceuticals for environmental risk assessment: Towards adequate and feasible first-tier selection.
    Roos V; Gunnarsson L; Fick J; Larsson DG; Rudén C
    Sci Total Environ; 2012 Apr; 421-422():102-10. PubMed ID: 22361586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human pharmaceuticals in surface waters. Implementation of a prioritization methodology and application to the French situation.
    Besse JP; Garric J
    Toxicol Lett; 2008 Jan; 176(2):104-23. PubMed ID: 18077113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are pharmaceuticals potent environmental pollutants? Part I: environmental risk assessments of selected active pharmaceutical ingredients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):67-87. PubMed ID: 16257037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted critical environmental concentrations for 500 pharmaceuticals.
    Fick J; Lindberg RH; Tysklind M; Larsson DG
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):516-23. PubMed ID: 20816909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentrations and mass loadings of cardiovascular pharmaceuticals in healthcare facility wastewaters.
    Nagarnaik P; Batt A; Boulanger B
    J Environ Monit; 2010 Nov; 12(11):2112-9. PubMed ID: 20862442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are pharmaceuticals potent environmental pollutants? Part II: environmental risk assessments of selected pharmaceutical excipients.
    Carlsson C; Johansson AK; Alvan G; Bergman K; Kühler T
    Sci Total Environ; 2006 Jul; 364(1-3):88-95. PubMed ID: 16260028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Source characterization of nervous system active pharmaceutical ingredients in healthcare facility wastewaters.
    Nagarnaik P; Batt A; Boulanger B
    J Environ Manage; 2011 Mar; 92(3):872-7. PubMed ID: 21094579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting monitoring data in environmental exposure modelling and risk assessment of pharmaceuticals.
    Boxall AB; Keller VD; Straub JO; Monteiro SC; Fussell R; Williams RJ
    Environ Int; 2014 Dec; 73():176-85. PubMed ID: 25127044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No human risks with pharmaceuticals in water.
    Cooney CM
    Environ Sci Technol; 2005 Oct; 39(19):397A. PubMed ID: 16245799
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An environmental fate, exposure and risk assessment of ethylene oxide from diffuse emissions.
    Staples CA; Gulledge W
    Chemosphere; 2006 Oct; 65(4):691-8. PubMed ID: 16516948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of human pharmaceutical concentrations in raw municipal wastewater and yellowwater.
    Winker M; Faika D; Gulyas H; Otterpohl R
    Sci Total Environ; 2008 Jul; 399(1-3):96-104. PubMed ID: 18455216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probabilistic environmental risk characterization of pharmaceuticals in sewage treatment plant discharges.
    Christensen AM; Markussen B; Baun A; Halling-Sørensen B
    Chemosphere; 2009 Oct; 77(3):351-8. PubMed ID: 19682723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prioritization of pharmaceuticals based on risks to aquatic environments in Kazakhstan.
    Aubakirova B; Beisenova R; Boxall AB
    Integr Environ Assess Manag; 2017 Sep; 13(5):832-839. PubMed ID: 28120523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceuticals in water, fish and osprey nestlings in Delaware River and Bay.
    Bean TG; Rattner BA; Lazarus RS; Day DD; Burket SR; Brooks BW; Haddad SP; Bowerman WW
    Environ Pollut; 2018 Jan; 232():533-545. PubMed ID: 29032907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.